Recently, Baidu and Sanofi signed a cooperation agreement. In the future, both parties will integrate the mRNA sequence design optimization algorithm platform LinearDesign independently developed by Baidu into the product design pipeline of Sanofi. Sanofi will use this platform to optimize the design and development of mRNA for the treatment and prevention of human diseases.
In October this year, Baidu and Microorganism, an mRNA drug company, jointly announced that LinearDesign had completed the biological verification of the molecular design of COVID-19 mRNA vaccine. The experimental results show that the vaccine designed by LinearDesign is significantly superior to the traditional design (benchmark sequence) in terms of stability, protein expression level and immunogenicity and other key indicators.
The above achievements cannot be separated from the technical support of artificial intelligence. According to the latest data of Smart Bud, Baidu and its affiliates have more than 5400 patent applications in 126 countries/regions around the world. Among them, there are more than 5300 invention patents, accounting for more than 98%.
According to the further analysis of the above AI patents, Baidu’s current patent layout in this field is mainly concentrated in the professional technology fields such as voice recognition, deep learning, neural network, voice interaction, automatic driving, etc.
